"Carcinoembryonic Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment.
| Descriptor ID |
D002272
|
| MeSH Number(s) |
D12.776.395.550.200.210 D12.776.543.550.200.210 D23.050.285.329 D23.050.301.350.210 D23.101.140.300
|
| Concept/Terms |
Carcinoembryonic Antigen- Carcinoembryonic Antigen
- Antigen, Carcinoembryonic
- CD66e Antigen
- Antigens, CD66e
- CD66e Antigens
- Antigen, CD66e
|
Below are MeSH descriptors whose meaning is more general than "Carcinoembryonic Antigen".
Below are MeSH descriptors whose meaning is more specific than "Carcinoembryonic Antigen".
This graph shows the total number of publications written about "Carcinoembryonic Antigen" by people in this website by year, and whether "Carcinoembryonic Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 5 | 7 |
| 1996 | 1 | 2 | 3 |
| 1997 | 1 | 4 | 5 |
| 1998 | 2 | 4 | 6 |
| 1999 | 1 | 7 | 8 |
| 2000 | 0 | 4 | 4 |
| 2001 | 2 | 5 | 7 |
| 2002 | 1 | 2 | 3 |
| 2003 | 0 | 3 | 3 |
| 2004 | 1 | 3 | 4 |
| 2005 | 0 | 3 | 3 |
| 2006 | 1 | 6 | 7 |
| 2007 | 1 | 3 | 4 |
| 2008 | 2 | 0 | 2 |
| 2009 | 1 | 2 | 3 |
| 2010 | 2 | 4 | 6 |
| 2012 | 4 | 2 | 6 |
| 2013 | 1 | 2 | 3 |
| 2014 | 0 | 2 | 2 |
| 2015 | 1 | 4 | 5 |
| 2016 | 1 | 3 | 4 |
| 2017 | 0 | 1 | 1 |
| 2018 | 2 | 1 | 3 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 1 | 2 |
| 2022 | 0 | 3 | 3 |
| 2024 | 1 | 4 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Carcinoembryonic Antigen" by people in Profiles.
-
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials. Nat Commun. 2024 May 15; 15(1):4091.
-
Serum Tumor Markers and Outcomes in Patients With Appendiceal Adenocarcinoma. JAMA Netw Open. 2024 02 05; 7(2):e240260.
-
The effects of oxaliplatin-based?adjuvant?chemotherapy?in?high-risk?stage?II?colon?cancer with mismatch repair-deficient: a retrospective study. BMC Cancer. 2024 Feb 02; 24(1):164.
-
ASO Author Reflections: The Value of Serum CEA for Prognostication at Staging and Response Evaluation in Patients with Localized Pancreatic Adenocarcinoma and Nonelevated CA19-9. Ann Surg Oncol. 2024 03; 31(3):1842-1843.
-
Serum CEA as a Prognostic Marker for Overall Survival in Patients with Localized Pancreatic Adenocarcinoma and Non-Elevated CA19-9 Levels Treated with FOLFIRINOX as Initial Treatment: A TAPS Consortium Study. Ann Surg Oncol. 2024 Mar; 31(3):1919-1932.
-
The Pathologic Complete Response Ratio of Liver Metastases Represents a Valuable Prognostic Indicator. Pathol Oncol Res. 2022; 28:1610663.
-
ESE3-positive PSCs drive pancreatic cancer fibrosis, chemoresistance and poor prognosis via tumour-stromal IL-1?/NF-?B/ESE3 signalling axis. Br J Cancer. 2022 11; 127(8):1461-1472.
-
Detection of recurrent colorectal cancer with high specificity using a reporting threshold for circulating tumor DNA methylated in BCAT1 and IKZF1. Cancer. 2022 05 15; 128(10):1921-1928.
-
Threshold Change in CEA as a Predictor of?Non-Progression to First-Line Systemic Therapy in Metastatic Colorectal Cancer Patients With Elevated CEA. J Natl Cancer Inst. 2020 11 01; 112(11):1127-1136.
-
Phase I Study of P-cadherin-targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors. Clin Cancer Res. 2020 11 15; 26(22):5830-5842.